International, post-authorisation non-interventional study to evaluate real-life effectiveness, safety and utilisation patterns of Octapharma's FVIII concentrates Nuwiq, Octanate, and Wilate in previously untreated and minimally treated severe haemophilia A patients in routine clinical practice.
Male and female patients of any age and ethnicity
Severe haemophilia A (FVIII:C<1%)
Decision to prescribe Octapharma's FVIII concentrate before enrollment into the study
Either
Diagnosis with a coagulation disorder other than haemophilia A
Concomitant treatment with any systemic immunosuppressive drug
Participation in an interventional clinical trial during the time period evaluated
Participation in another non-interventional study of Octapharma
Octapharma
Lead sponsor